FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday

Bristol Myers Squibb has received a March 27 PDUFA date for its anti-BCMA CAR-T cell therapy. The priority review action date sets Bristol Myers up to win approval for the bluebird bio-partnered drug in time to satisfy the terms of its acquisition of Celgene.